NRAS and melanoma: (2012) identified BRAF mutations in 50% of melanomas, NRAS mutations in 30%, NF1 mutations in 12–23%, and PTEN mutations in 5–40%, highlighting their role in melanoma progression and therapeutic responsiveness (20).